-
Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO) collaboration agreement with Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; SPH). This new agreement follows the success of their initial collaboration in 2020 and aims to further enhance the co-marketing efforts for prescription drugs. Building…
-
Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market
•
Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of Japan-based Sumitomo Pharma, has expressed strong optimism about the company’s prospects in the local market in an interview with Shanghai Daily. Koketsu emphasized that China, as the world’s second-largest pharmaceutical market, holds strategic significance for…
-
Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management
•
Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506) for their women’s health product Myfembree (relugolix + estradiol + norethindrone acetate). The approval is for the management of moderate-to-severe pain associated with endometriosis in pre-menopausal women, supported by late-stage data from multiple trials. Previous…
-
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have revealed a setback in late-stage clinical trials for the potential first-in-class trace amine-associated receptor 1 (TAAR1) agonist, ulotaront, as a treatment for schizophrenia. Topline data from the Phase III DIAMOND 1 and DIAMOND 2 studies…
-
Sumitomo Pharma to Invest $30 Million in China for New Product Development
•
Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of USD 30 million in the China market, as reported by Shine. This investment, as stated by Yoshitaka Koketsu, president and CEO of Sumitomo Pharma (China) Co., Ltd, is aimed at developing and launching new products…
